Format

Send to

Choose Destination
Trends Neurosci. 2006 May;29(5):286-93. Epub 2006 Apr 17.

LRRK2 in Parkinson's disease: protein domains and functional insights.

Author information

1
Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, FL 32224, USA.

Abstract

Parkinson's disease (PD) is the most common motor neurodegenerative disease. Mutations in the gene encoding leucine-rich repeat kinase 2 (LRRK2) have been linked recently with autosomal-dominant parkinsonism that is clinically indistinguishable from typical, idiopathic, late-onset PD. Thus, the protein LRRK2 has emerged as a promising therapeutic target for treatment of PD. LRRK2 is extraordinarily large and complex, with multiple enzymatic and protein-interaction domains, each of which is targeted by pathogenic mutations in familial PD. This review places the PD-associated mutations of LRRK2 in a structural and functional framework, with the ultimate aim of deciphering the molecular basis of LRRK2-associated pathogenesis. This, in turn, should advance our understanding and treatment of familial and idiopathic PD.

PMID:
16616379
DOI:
10.1016/j.tins.2006.03.006
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center